SCHEMBL4499794

SCHEMBL4499794

Nc1n[nH]c2cc(-c3cccc4ccccc34)ccc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 4/20 0.62
PDPK1 O15530 12/20 0.59
AURKB Q96GD4 5/20 0.56
AURKA O14965 4/20 0.56
TGFBR1 P36897 4/20 0.56
SCN5A Q14524 1/20 0.55
SCN9A Q15858 1/20 0.55
KDM4E B2RXH2 1/20 0.51
CYP3A4 P08684 1/20 0.51
GAA P10253 1/20 0.51
JAK3 P52333 2/20 0.51
JAK1 P23458 1/20 0.51
TYK2 P29597 1/20 0.51
KDR P35968 4/20 0.50
ROCK1 Q13464 3/20 0.50
CHUK O15111 1/20 0.50
RPS6KB1 P23443 1/20 0.50
CDK2 P24941 1/20 0.50
SYK P43405 1/20 0.50
MAP3K5 Q99683 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6478211 0.80 JAK2 (0.78) JAK2PDPK1AURKBAURKATGFBR1
SCHEMBL12907205 0.80 JAK2 (0.64) JAK2PDPK1AURKBAURKATGFBR1
SCHEMBL12907193 0.80 JAK2 (0.64) JAK2PDPK1AURKBAURKATGFBR1
SCHEMBL4487734 0.80 JAK2 (0.64) JAK2PDPK1AURKBAURKATGFBR1
SCHEMBL5253045 0.77 CHEK1 (0.73) KDRCDK2FGFR1
SCHEMBL12907241 0.77 JAK2 (1.00) JAK2PDPK1AURKBAURKATGFBR1
SCHEMBL3361070 0.77 JAK2 (1.00) JAK2PDPK1AURKBAURKATGFBR1
SCHEMBL12907209 0.77 SCN5A (0.59) JAK2PDPK1AURKBAURKATGFBR1
SCHEMBL4494105 0.77 SCN5A (0.62) JAK2PDPK1AURKBAURKATGFBR1
SCHEMBL13525177 0.75 PDPK1 (0.55) JAK2PDPK1AURKBAURKATGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1506176-B1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PFIZER ITALIA SRL (IT) 2013-04-24 EP disclosed
US-7632854-B2 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2009-12-15 US disclosed
US-20060106083-A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2006-05-18 US disclosed
EP-1506176-A1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2005-02-16 EP disclosed
WO-2003097610-A1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106083-A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K15, MAP3K3, MAP3K20 JAK2 416/4885PDPK1 34/4885AURKB 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.